·PIB

Dr. Jitendra Singh visits Italy based 'International Centre for Genetic Engineering and Biotechnology' (ICGEB) at Trieste, highlights India's growing role in global biotechnology research, innovation and scientific coope...

FlashcardsQuick reviseKey facts. One by one.Start →
In this note
  1. At a Glance
  2. Why in the News
  3. Background & Evolution
  4. Core Static Facts
  5. Multi-Dimensional Analysis
  6. Recent Developments (last 12–18 months)
  7. Prelims Hooks
  8. What the Press Release Tells Us and What It Leaves Out
  9. Why a Biofoundry Alone Will Not Build a $300 Billion Bioeconomy
  10. The Biosafety Questions That Come With This Research
  11. Is Paying Into a Shared Lab Worth It for India?
  12. What DBT and Its Partners Should Do Next
  13. Anchors for Answers
  14. Mains Relevance
  15. Related Topics to Study Next
  16. NCERT Concepts to Revise
  17. Common Errors / Trap Areas

1. At a Glance

  • ICGEB (International Centre for Genetic Engineering and Biotechnology) is an international, intergovernmental research organisation. It promotes advanced research, higher education, training and technology transfer in genetic engineering, biotechnology and life sciences. [1]
  • It has three components in Trieste (Italy), New Delhi (India) and Cape Town (South Africa). They are parts of one organisation, not separate bodies. [1]
  • Why it matters for UPSC: it brings together India's BioE3 policy, the biomanufacturing push, science diplomacy and South-South cooperation. That makes it a GS-II (international institutions) and GS-III (biotechnology) crossover. [1]
  • India is a member-partner. The Department of Biotechnology (DBT) supports the New Delhi component. [1][2]

2. Why in the News

  • 16 Nov 2026: Dr. Jitendra Singh, Union MoS (Independent Charge) for Science & Technology, visited ICGEB Trieste, Italy. He reviewed its facilities and highlighted India's role in global biotechnology research, innovation and cooperation. [1]
  • Facilities shown to him at Trieste: [1]
  • a newly built Biosafety Level 3 (BSL-3) laboratory
  • a high-throughput screening facility in the Functional Cell Biology laboratory
  • a biopharmaceutical production and training facility under the Biotechnology Development Unit

  • The release links ICGEB New Delhi's research areas to India's BioE3 policy. [1]

3. Background & Evolution

  • Nature: an organisation set up by governments, not a national institute. It operates across member countries. [1]
  • Indian component: based at the ICGEB Campus, Aruna Asaf Ali Marg, New Delhi – 110067. DBT lists it among the international bodies it deals with. [2]
  • DBT's role at New Delhi: it supports R&D programmes, innovation incubation and human resource development. [1]
  • Milestones relevant to India:
  • Aug 2024: Union Cabinet approved the BioE3 (Biotechnology for Economy, Environment and Employment) Policy to foster high-performance biomanufacturing. [3]
  • India's first biofoundry for microbial biomanufacturing was inaugurated at ICGEB's India component. [1]
  • 2023–2026: 67 researchers from 22 countries trained or began training at ICGEB New Delhi. [1]
  • Nov 2026: the ministerial visit to Trieste. [1]

  • Origin facts not verified from whitelisted sources: ICGEB is commonly described as starting in 1983 as a UNIDO project and later becoming autonomous. Check this against the official ICGEB or UN documents before using it in an answer.

4. Core Static Facts

Item Fact
Full form International Centre for Genetic Engineering and Biotechnology [1]
Type International intergovernmental research organisation [1]
Components Trieste (Italy), New Delhi (India), Cape Town (South Africa) [1]
Mandate Research, higher education, training, technology transfer in genetic engineering, biotechnology and life sciences [1]
Indian nodal department Department of Biotechnology (DBT), Ministry of Science & Technology [1][2]
New Delhi address Aruna Asaf Ali Marg, New Delhi – 110067 [2]
Training reach (New Delhi) 67 researchers from 22 countries, 2023–2026 [1]
India's first microbial-biomanufacturing biofoundry At ICGEB India component [1]
New Trieste facility shown BSL-3 high-containment lab [1]
Linked Indian policy BioE3 Policy, Cabinet-approved Aug 2024 [1][3]

Key terms:

  • BSL-3: a high-containment lab for work on infectious agents. At Trieste it is linked to research on monoclonal antibodies against infectious diseases. [1]
  • High-throughput screening: testing many samples quickly in cell-based research. [1]
  • Biofoundry: a facility for engineering microbes to manufacture products. It helps move research into industrial processes. [1]
  • BioE3: a framework that brings biotechnology, engineering and digitalisation together. [4]

ICGEB India research areas aligned with BioE3: [1]

  • bio-based chemicals and enzymes
  • climate-resilient agriculture
  • carbon capture and utilisation
  • precision biotherapeutics
  • marine and space biomanufacturing

5. Multi-Dimensional Analysis

Scientific / Technological

  • Three separate research strands are showcased under ICGEB India: [1]
  • genome-edited crops (agriculture)
  • biological carbon capture (climate)
  • enzyme/yeast-based ethanol systems (bioenergy)

  • In health, the work covers monoclonal antibodies (precision biotherapeutics) and vaccines (molecular medicine). [1]

  • Trieste's BSL-3 and high-throughput screening facilities make high-containment, large-scale infectious-disease research possible. [1]

Geopolitical / Strategic (science diplomacy)

  • ICGEB is a platform for working with developing and emerging economies in Asia and Africa through joint research, training and technology transfer. [1]
  • Training 67 researchers from 22 countries at New Delhi builds India's soft power as a knowledge partner for the Global South. [1]
  • Hosting one of only three components gives India institutional weight inside a multilateral science body. [1]

Economic

  • BioE3 targets high-performance biomanufacturing, so ICGEB's work on biofoundries and enzymes feeds directly into growing the bioeconomy. [1][3]
  • Biopharma production and training at Trieste, and incubation support at New Delhi, connect lab research to industry. [1]

Environmental

  • Carbon capture and utilisation, climate-resilient agriculture and bio-ethanol systems support decarbonisation and food security. [1]

Ethical / Governance

  • Genome editing and BSL-3 work raise biosafety and biosecurity concerns: containment standards, dual-use risks and how genome-edited crops are regulated.
  • India co-funds a multilateral body, which raises questions of accountability for that money and fair sharing of intellectual property.

6. Recent Developments (last 12–18 months)

  • 16 Nov 2026: Dr. Jitendra Singh visited ICGEB Trieste, toured the BSL-3, high-throughput screening and biopharma facilities, and highlighted the alignment with BioE3. [1]
  • 2023–2026: 67 researchers from 22 countries trained at ICGEB New Delhi. [1]
  • Within this period (exact date not verified from a whitelisted source): India's first biofoundry for microbial biomanufacturing was inaugurated at ICGEB New Delhi. [1]

7. Prelims Hooks

  • ICGEB is an intergovernmental organisation, not a national institute of India or Italy. [1]
  • ICGEB components: Trieste (Italy), New Delhi (India), Cape Town (South Africa). [1]
  • The Indian component is in New Delhi, not Hyderabad or Bengaluru. [1][2]
  • Indian department supporting ICGEB New Delhi: Department of Biotechnology (DBT). [1]
  • India's first biofoundry for microbial biomanufacturing is at ICGEB New Delhi. [1]
  • The new BSL-3 lab shown in Nov 2026 is at Trieste, not New Delhi. [1]
  • The high-throughput screening facility is in Trieste's Functional Cell Biology laboratory. [1]
  • The biopharmaceutical production and training facility falls under the Biotechnology Development Unit. [1]
  • 67 researchers from 22 countries trained at ICGEB New Delhi in 2023–2026. [1]
  • BioE3 stands for Biotechnology for Economy, Environment and Employment. Cabinet approved it in Aug 2024. [3]
  • BioE3 brings together biotech, engineering and digitalisation. [4]
  • BioE3-aligned ICGEB areas include carbon capture and utilisation and marine and space biomanufacturing. [1]
  • The minister who visited was Dr. Jitendra Singh, MoS (I/C) Science & Technology. [1]

8. What the Press Release Tells Us and What It Leaves Out

  • The release lists facilities but gives no results
  • It describes labs and policy links: BSL-3, high-throughput screening, a biopharma unit, BioE3 alignment [1].
  • It gives no figures for India's money paid to ICGEB, patents filed, technologies transferred to industry, or products made.
  • So the note can say what ICGEB has. It cannot yet say what ICGEB has delivered for India.

  • The training number is small when you work it out

  • 67 researchers from 22 countries over 2023–2026 [1] is about 20 people a year, or about 3 per country.
  • That is a useful start for South-South cooperation (developing countries helping each other). But it is too small to call India the main 'knowledge partner' of the Global South.
  • In an answer, use the figure as early proof of intent, not as proof of large reach.

  • The newest high-containment lab is in Italy, not India

  • The new BSL-3 lab and the screening facility shown during the visit are at Trieste [1].
  • India hosts one of the three components [1]. But for this type of advanced infectious-disease work, its scientists still depend on a facility abroad.

  • Key dates are still unconfirmed

  • The biofoundry inauguration date and ICGEB's origin as a UNIDO project are not confirmed from official sources (see the note's verification flag).
  • Do not build an argument on these dates until you have checked them.

9. Why a Biofoundry Alone Will Not Build a $300 Billion Bioeconomy

  • The target needs fast and steady growth
  • India's bioeconomy grew from about $10 billion in 2014 to $165.7 billion in 2024. The target is $300 billion by 2030 [5].
  • To get from $165.7 billion to $300 billion in six years, the bioeconomy must grow by about 10% every single year.
  • Research labs like ICGEB's produce new methods. The growth itself must come from factories that make products at large scale.

  • The step from lab to factory is where projects get stuck

  • A biofoundry (a facility that engineers microbes to make products) helps a process work in the lab [1].
  • A company still needs large fermentation tanks (vessels where microbes make the product at scale), regulatory approval and buyers before it earns money.
  • That is why BioE3 also plans separate Biomanufacturing and Bio-AI hubs next to biofoundries [5]. The ICGEB biofoundry is only the first step in this chain.

  • India spends little on research overall

  • GERD (Gross Expenditure on Research and Development, which is all R&D spending in the country) was about 0.64% of GDP [6].
  • India's long-stated goal is 2% [6].
  • With so little money for research, a few showcase institutions like ICGEB New Delhi end up carrying too much of the load.

  • Most R&D money has come from government

  • Private industry provided only around 36% of R&D spending in the period PRS analysed [6].
  • Biomanufacturing at scale needs private companies to put in money. Government-funded labs cannot fill that gap alone.

10. The Biosafety Questions That Come With This Research

  • Dual-use risk: the same knowledge can protect or harm
  • Dual-use means research meant for good, like antibodies against infections, can also teach someone how to make a germ more dangerous.
  • BSL-3 work on infectious agents at Trieste [1] is useful for preparing against pandemics. It also needs strict checks on who can get the materials and the results.
  • When an organisation is shared by several governments, the rules for each lab come partly from the host country. India should know which standards apply at each component.

  • Genome-edited crops are a live public debate

  • ICGEB India works on genome-edited crops [1]. India treats SDN-1 and SDN-2 edits (small changes with no foreign DNA added) more lightly than GM crops (see the note's section 9).
  • Supporters say these edits are like natural mutations, so lighter rules make sense.
  • Critics say lighter rules mean less public testing before the crop reaches farmers.
  • In Mains, present both views. Then argue for openness: publish the safety data for each crop that is released.

11. Is Paying Into a Shared Lab Worth It for India?

  • The strongest objection
  • India now has its own biofoundries and BioE3 hubs [1][5]. Why send money to a body whose newest labs are in Italy [1]?
  • The same rupees could fund Indian labs that India controls fully.

  • The honest answer: it is worth it, but the case is not yet proven

  • Shared costs: one BSL-3 lab and screening facility are used by many member countries. India does not have to build every expensive facility alone.
  • Diplomatic return: training foreign researchers in New Delhi [1] builds long-term ties with Asia and Africa that a purely national lab cannot build.
  • What the critic gets right: without public data on India's payments and what it gets back (see the first section above), no one can show that this beats spending at home.

12. What DBT and Its Partners Should Do Next

  • DBT should publish a yearly ICGEB report card
  • It should list India's payments, joint papers, patents, technologies licensed to Indian companies, and where the trainees went next.
  • This answers the accountability question the note raises in section 5, and turns the soft-power claim into numbers that can be checked.

  • DBT and BIRAC should link the ICGEB biofoundry to the BioE3 hubs

  • BioE3 already plans Biomanufacturing and Bio-AI hubs [5].
  • Each hub should take on processes proven at the ICGEB New Delhi biofoundry, such as enzymes and bio-based chemicals [1].
  • This closes the lab-to-factory gap and supports the roughly 10% yearly growth the $300 billion target needs [5].

  • The Ministry of Science and Technology should bring in private money

  • With GERD at about 0.64% of GDP and the 2% goal unmet [6], ICGEB-linked projects should require a company co-funding partner before moving to the scale-up stage.

  • India should seek a high-containment lab under ICGEB at home

  • A BSL-3 facility at New Delhi, matching Trieste's [1], would let Indian and Global South researchers do infectious-disease work without travelling to Europe.
  • It should come with strict dual-use rules: control over who can enter, who handles samples, and who can see results.

13. Anchors for Answers

  • Data: India's bioeconomy grew from $10 billion (2014) to $165.7 billion (2024). Target: $300 billion by 2030 [5]
  • Data: 67 researchers from 22 countries trained at ICGEB New Delhi, 2023–2026, about 20 a year [1]
  • Data: GERD about 0.64% of GDP, against a 2% goal. Private share was around 36% [6]
  • Report/Committee: PRS Legislative Research, Demand for Grants Analysis: Science and Technology [6]
  • Scheme: BioE3 Policy (Aug 2024), with Biomanufacturing and Bio-AI hubs and biofoundries: the route from ICGEB lab work to factory production [3][5]

14. Mains Relevance

15. Related Topics to Study Next

  • BioE3 Policy (2024): the policy ICGEB India's research is aligned with.
  • National Biofoundry Network / Bio-AI hubs: the infrastructure built on the biofoundry model.
  • DBT and BIRAC: the departmental and incubation support behind biotech start-ups.
  • Genome-edited crops and SDN-1/SDN-2 regulatory exemptions: directly tied to ICGEB's agri-biotech work.
  • Biosafety levels (BSL-1 to BSL-4) and the Cartagena Protocol: the containment and biosafety governance framework.
  • Monoclonal antibodies vs vaccines: a distinction often tested in health-biotech questions.
  • UNIDO and other UN-system bodies: relevant to ICGEB's origin and institutional lineage.
  • India–Italy S&T cooperation: the bilateral context of the Trieste visit.

16. NCERT Concepts to Revise

  • BioE3 policy (Economy): The 2024 policy that ICGEB India's research is aligned with; it drives biomanufacturing and the bioeconomy target.
  • Science diplomacy (Polity): ICGEB is a shared science body; India uses it to build ties with Asia and Africa.
  • Bioeconomy (Economy): The $300 billion bioeconomy target is the economic goal that biofoundries and BioE3 serve.
  • Global South (Polity): India trains researchers from developing countries at ICGEB New Delhi, presenting itself as their knowledge partner.
  • Soft power (Polity): Training foreign researchers builds India's influence through knowledge and cooperation rather than force or payment.
  • Technology transfer (Economy): Moving know-how to member countries is a core mandate of ICGEB.
  • Intellectual property rights (Economy): The note raises fair sharing of patents and IP from jointly funded research.
  • Food security (Economy): Genome-edited, climate-resilient crops at ICGEB aim to improve food availability and security.
  • Climate change (Geography): Carbon capture and utilisation research at ICGEB is a biotechnology response to climate change.
  • Accountability (Polity): The note asks DBT to publish what India pays ICGEB and what it gets back.

17. Common Errors / Trap Areas

  • Treating ICGEB as an Indian or Italian national institute. It is intergovernmental, with three components of one body. [1]
  • Putting the BSL-3 lab in New Delhi. The newly built BSL-3 shown in the visit is at Trieste. [1]
  • Wrong ministry. ICGEB New Delhi is supported by DBT, not DST, ICMR or MoEFCC. [1] Watch for "DST-ICGEB" in news coverage of the biofoundry and check which department is named in the actual question.
  • Wrong expansion of BioE3. It is Biotechnology for Economy, Environment and Employment, not "Energy" or "Ecology". [3]
  • Confusing monoclonal antibodies with vaccines. The release puts antibodies under precision biotherapeutics against infectious diseases, and vaccines under molecular medicine. [1]

Sources

  1. 1Press Release Page, Press Information Bureau (Dr. Jitendra Singh visits ICGEB Trieste)pib.gov.in · tier 1
  2. 2International Centre For Genetic Engineering and Biotechnology, Department of Biotechnologydbtindia.gov.in · tier 1
  3. 3PIB specific document on BioE3 Policy (Aug 2024)static.pib.gov.in · tier 1
  4. 4BioE3 Policy Brochure, Department of Biotechnologydbtindia.gov.in · tier 1
  5. 5PIB specific document on India's bioeconomy and BioE3 (Sep 2025)static.pib.gov.in · tier 1
  6. 6Demand for Grants 2024-25 Analysis: Science and Technology, PRS Legislative Researchprsindia.org · tier 1

Mains Q&A on this note

NCERT concepts in this note

Also on 16 November

All 16 November articles →